Eli Lilly and Company drugs

39 results

  • amyvid

    (Florbetapir F 18)
    Eli Lilly and Company
    Amyvid is indicated for PET imaging to assess β-amyloid plaque density in adults with cognitive impairment being evaluated for Alzheimer's Disease (AD) and other cognitive decline causes. It serves as an adjunct to other diagnostic assessments but does not confirm a diagnosis or predict dementia development.

  • bamlanivimab

    (Bamlanivimab)
    Eli Lilly and Company

  • baqsimi

    (glucagon)
    Eli Lilly and Company
    BAQSIMI™ is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes aged 4 years and older.

  • baricitinib

    (baricitinib)
    Eli Lilly and Company

  • basaglar

    (Insulin glargine)
    Eli Lilly and Company
    BASAGLAR® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus, and in adults with type 2 diabetes mellitus. It is not recommended for treating diabetic ketoacidosis.

  • bebtelovimab

    (Bebtelovimab)
    Eli Lilly and Company

  • cialis

    (Tadalafil)
    Eli Lilly and Company
    CIALIS® is indicated for the treatment of erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and both conditions simultaneously (ED/BPH). If used with finasteride for BPH, treatment is recommended for up to 26 weeks due to diminishing benefits thereafter.

  • cymbalta

    (Duloxetine hydrochloride)
    Eli Lilly and Company
    CYMBALTA® is indicated for the treatment of major depressive disorder, generalized anxiety disorder (in adults and children 7+), diabetic peripheral neuropathic pain, fibromyalgia (in adults and those 13+), and chronic musculoskeletal pain in adults.

  • cyramza

    (ramucirumab)
    Eli Lilly and Company
    CYRAMZA® is indicated for advanced gastric cancer, non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and hepatocellular carcinoma (HCC) in specific settings, often after prior chemotherapy or specific genetic mutations. It is used alone or in combination with other therapies based on cancer type and progression.

  • ebglyss

    (lebrikizumab-lbkz)
    Eli Lilly and Company
    EBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients aged 12 and older, weighing at least 40 kg, whose condition is inadequately controlled with topical therapies or when such therapies are not appropriate. It may be used alone or with corticosteroids.